Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.68

-2.4%

Dec 12 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: former_pgs who wrote (14241)	11/20/2004 3:10:56 PM
From: scaram(o)uche	Read Replies (2) of 52153

yahoo.reuters.com quotes, and what the analysts really (IMO) meant to say..... >> Jim Reddoch, an analyst at Friedman, Billings, Ramsey & Co. said, "Peak sales of the drug for lung cancer are probably going to be in the $400 million to $500 million range instead of the $1 billion range investors expected." << What he really meant to say..... "instead of the $1 billion range some investors were guided to by some analysts." >> Piper Jaffray analyst Thomas Wei said the inclusion of the EGFR data in the package insert "suggests that the FDA found the analysis important for physicians to consider." "If physicians choose to limit their usage to EGFR-positive patients, our estimates for sales for lung cancer ... may prove (too) aggressive." << What he really meant to say..... "While I've given my opinion, it's obvious that I'm not up to speed on the issue. I'll get back to you."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next